Despite an increasing number of patients suffering from an acute coronary syndrome under novel oral anticoagulant therapy, specific treatment recommendations for anticoagulation are still lacking. For this reason, the German Society of Cardiology and the German Association of Interdisciplinary Intensive Care and Emergency Medicine developed a consensus statement for the treatment of these patients with the aim to summarize the current evidence and to increase the safety of this special patient group.
Trotz einer zunehmenden Anzahl von Patienten, welche unter einer Dauertherapie mit neuen oralen Antikoagulanzien ein akutes Koronarsyndrom erleiden, existierten bisher keine Handlungsempfehlungen für deren prähospitale antikoagulatorische Therapie. Aus diesem Grund formulierten die Deutsche Gesellschaft für Kardiologie und die Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin ein Konsensuspapier zur Therapie dieser speziellen Patientengruppe. Um die Sicherheit dieses Patientenkollektives zu erhöhen, ist es Ziel des Konsensuspapiers, die aktuelle Evidenzlage in strukturierten Empfehlungen zusammenzufassen.

暂无摘要。

Numerous definitions have been proposed for the diagnosis of myocardial infarction (MI) after coronary revascularization. The universal definition for MI designates post procedural biomarker thresholds for defining percutaneous coronary intervention (PCI)-related MI (type 4a) and coronary artery bypass grafting (CABG)-related MI (type 5), which are of uncertain prognostic importance. In addition, for both the MI types, cTn is recommended as the biomarker of choice, the prognostic significance of which is less well validated than CK-MB. Widespread adoption of a MI definition not clearly linked to subsequent adverse events such as mortality or heart failure may have serious consequences for the appropriate assessment of devices and therapies, may affect clinical care pathways, and may result in misinterpretation of physician competence. Rather than using an MI definition sensitive for small degrees of myonecrosis (the occurrence of which, based on contemporary large-scale studies, are unlikely to have important clinical consequences), it is instead recommended that a threshold level of biomarker elevation which has been strongly linked to subsequent adverse events in clinical studies be used to define a \"clinically relevant MI.\" The present document introduces a new definition for \"clinically relevant MI\" after coronary revascularization (PCI or CABG), which is applicable for use in clinical trials, patient care, and quality outcomes assessment.

Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker is a key strategy to reduce platelet reactivity and to prevent thrombotic events in patients treated with percutaneous coronary intervention. In an earlier consensus document, we proposed cutoff values for high on-treatment platelet reactivity to adenosine diphosphate (ADP) associated with post-percutaneous coronary intervention ischemic events for various platelet function tests (PFTs). Updated American and European practice guidelines have issued a Class IIb recommendation for PFT to facilitate the choice of P2Y12 receptor inhibitor in selected high-risk patients treated with percutaneous coronary intervention, although routine testing is not recommended (Class III). Accumulated data from large studies underscore the importance of high on-treatment platelet reactivity to ADP as a prognostic risk factor. Recent prospective randomized trials of PFT did not demonstrate clinical benefit, thus questioning whether treatment modification based on the results of current PFT platforms can actually influence outcomes. However, there are major limitations associated with these randomized trials. In addition, recent data suggest that low on-treatment platelet reactivity to ADP is associated with a higher risk of bleeding. Therefore, a therapeutic window concept has been proposed for P2Y12 inhibitor therapy. In this updated consensus document, we review the available evidence addressing the relation of platelet reactivity to thrombotic and bleeding events. In addition, we propose cutoff values for high and low on-treatment platelet reactivity to ADP that might be used in future investigations of personalized antiplatelet therapy.

The current guidelines advocate distinct approaches (urgent reperfusion therapy) to patients with suspected acute coronary syndromes (ACS) presenting with ST elevation (STE) versus patients without STE on their electrocardiogram (ECG). This is based on the paradigm that STE represents ongoing transmural ischemia due to an acute occlusion of an epicardial coronary artery whereas the significance of other ECG findings is more contentious. The role of urgent coronary angiography in patients without STE is less clear and initial stabilization with conservative treatment is recommended. However, in some cases the distinction between STEMI and non-STE-ACS is difficult. Acute occlusion of a coronary artery may cause less than the current recommended threshold STE. On the other hand, many patients may have STE secondary to nonischemic etiology. In many patients with non-STE-ACS the coronary artery is not completely occluded at the time of presentation and there are rapid fluctuations in the severity of ischemia and hence, dynamic changes are observed in the ECG. Several ECG patterns associated with particular coronary anatomy and high-risk prognosis have been identified. Patients with ACS presenting with these high-risk patterns should probably be referred for coronary angiography with the possibility of urgent intervention with the goal of prevention of ischemic complications, rather than for immediate myocardial salvage, as in classic STEMI.